RayzeBio is a dynamic biotechnology company headquartered in San Diego, CA. Launched in late 2020 and recently acquired by Bristol Myers Squibb (BMS) as a wholly owned subsidiary, the company is focused on improving survival of people with cancer by harnessing the power of targeted radioisotopes. RayzeBio will operate as a standalone entity within the BMS organization, maintaining its biotech culture with the opportunity to leverage the best-in-class oncology capabilities of BMS. RayzeBio is developing innovative drugs against targets of solid tumors. The lead asset, RYZ101, is in Phase 3 testing for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), as well as earlier stage testing for patients with small cell lung cancer (SCLC). Led by a successful and experienced entrepreneurial team, RayzeBio aims to be the global leader in radiopharmaceuticals. The laboratory-based role offers an opportunity to help advance novel radiopharmaceutical therapies from laboratory into clinical testing. The candidate is responsible for developing, optimizing, and transferring biochemical and cell-based assays, including equilibrium binding assays, to support target validation, compound screening, and mechanism of action studies for various pipeline projects. A strong foundation in mammalian cell culture is essential. The ideal candidate will be a critical thinker and a technical problem solver who enjoys working in interdisciplinary drug discovery teams. The role requires an ability and willingness to work with radioactive isotopes.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Education Level
Associate degree
Number of Employees
5,001-10,000 employees